Vedolizumab
No
Yes
Medical Assistance Fund
Active ingredient: Vedolizumab
General information
Subsidy Information and Financing Scheme
[MAF] Vedolizumab (Entyvio) Infusion 300 mg
Additional clinical criteria applies
Treatment of adults with moderately to severely active Crohn’s disease who have failed both conventional therapy and anti-TNFα biologics.
Drug Guidance for Subsidy
Not Applicable
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Entyvio Infusion 300 mg |
|
